Although early results in phase I studies were promising, only one phase II study has been reported for the use of PD-1/PD-L1 inhibitors in DLBCL patients, “A single-arm, open-label, phase 2 study of nivolumab (BMS-936558) in subjects with relapsed or refractory DLBCL after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in subjects who are not candidates for ASCT”. Here, PDCD1 is linked to diffuse large B-cell lymphoma.